Detalhe da pesquisa
1.
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial.
Lancet Reg Health Am
; 18: 100423, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36618081
2.
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
Vaccine
; 40(13): 2068-2075, 2022 03 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35164986
3.
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
Vaccine
; 40(31): 4220-4230, 2022 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35691871